Joint Wear: A Modern Challenge
Joint wear is common with age and injury, and cartilage has very limited capacity to repair itself. Patients researching their options often encounter three related terms — the ChondroFiller injection, stem cell therapy, and Liquid Cartilage — and can understandably find the relationships between them unclear. They are distinct treatments suited to different clinical situations, and understanding the differences is the first step towards making an informed choice.
What Is the ChondroFiller Injection?
ChondroFiller is a Class III CE-marked type I collagen hydrogel scaffold, manufactured by Meidrix Biomedicals in Germany and imported into the UK under prescription. The material is acellular — it contains no cells — and self-gels within approximately three to five minutes of being placed in a joint, forming a porous three-dimensional matrix.
When used as a non-surgical outpatient treatment, it is delivered as an ultrasound-guided injection — no theatre, no incision, and no general anaesthetic. Once in the joint, the scaffold may settle over a worn surface, providing a supportive collagen layer that recruits the patient's own progenitor cells to migrate in and remodel the matrix. It is best understood as a joint-preserving, regenerative support rather than a guaranteed repair. Published clinical data on the device show MOCART repair-tissue scores in the range of around 80 and above at follow-up, indicating meaningful defect filling in suitable patients; benefits are nonetheless variable and outcomes depend on defect size, joint condition, and individual factors.
The ChondroFiller injection is particularly suited to accessible lesions and smaller joints, where the non-surgical delivery route offers a quicker, simpler experience and prompt return to normal activity. It is not a cure for arthritis and does not reverse established joint degeneration.
The Liquid Cartilage Surgical Protocol
Liquid Cartilage is not an injection and is not simply another name for ChondroFiller. It is the Lee Liquid Cartilage Protocol (LLC Protocol), Professor Paul Lee's keyhole surgical technique for cartilage regeneration in larger or load-bearing defects — typically the knee, hip, shoulder, or ankle.
During the procedure, the ChondroFiller scaffold is placed arthroscopically into the prepared defect under a dry carbon dioxide field to allow it to gel correctly, and is combined with biological adjuncts: autologous platelet-rich fibrin (PRF) as a primer coat, platelet-rich plasma (PRP) with tranexamic acid to reinforce anchorage and limit fibrinolysis, and — where clinically indicated — the patient's own mesenchymal stem cells (MSCs). This is genuine surgery: theatre, anaesthetic, and a structured rehabilitation programme are required, with protected weight-bearing typically for around two weeks and a graduated return to full activity over months.
Where MSCs are added within the Liquid Cartilage protocol, they are sourced from bone marrow aspirate concentrate (BMAC) or micro-fragmented adipose tissue (mFAT) harvested from the patient at the same operative sitting. Their role is primarily trophic and immunomodulatory — releasing signalling factors that support chondrogenesis and temper post-operative inflammation — working synergistically with the scaffold and fibrin environment rather than providing direct cellular replacement on their own.
How Standalone Stem Cell Therapy Differs
Standalone stem cell therapy for joint conditions — typically an injection of BMAC or processed fat-derived cells — is a separate approach that does not involve a scaffold. Cells are harvested, processed, and introduced into the joint, with the aim of providing trophic support and, in some patients, contributing to tissue repair. It is a multi-step process: harvesting requires a separate procedure (usually a bone marrow or fat aspiration), and the outcome depends on many individual factors including the degree of joint wear, cell concentration, and biological environment at the treatment site.
Evidence for standalone MSC injection in joint conditions is developing. Published series suggest improvements in pain and function scores in suitable patients, though results are variable and cartilage regeneration from injected cells alone is not reliably demonstrated in robust clinical trials. It remains most appropriate for patients with early-to-moderate joint wear who are not candidates for surgical intervention.
Choosing Between the Options
The three approaches sit at different points in the treatment spectrum. The ChondroFiller injection is the least invasive, well suited to accessible lesions and patients for whom surgery is not appropriate or desired. The Liquid Cartilage surgical protocol — ChondroFiller placed arthroscopically with biological adjuncts and optional MSCs — is designed for larger defects or load-bearing joints where a more controlled regenerative environment is needed. Standalone stem cell injection sits in a middle ground: more involved than a simple injection but without the full scaffold-and-surgery approach.
Suitability depends on the individual: defect size and location, the degree of underlying joint wear, patient age and activity level, and any contra-indications all need careful assessment. No single option is universally superior, and none guarantees cartilage regrowth or resolution of arthritis.
Conclusion
Joint wear presents real challenges, and the range of regenerative options available — including the ChondroFiller injection, the Liquid Cartilage keyhole surgical protocol, and standalone stem cell therapy — can be genuinely useful in the right clinical context. Understanding their differences is essential before any decision is made. For a personalised assessment, the London Cartilage Clinic on Harley Street offers specialist evaluation with realistic, evidence-based guidance on which pathway, if any, may suit your joint and your goals.
References
Corain, M., Zanotti, F., Giardini, M., Gasperotti, L., Invernizzi, E., Biasi, V., & Lavagnolo, U. (2023). The use of an acellular collagen matrix ChondroFiller Liquid for trapeziometacarpal osteoarthritis. Cartilage.
Frequently Asked Questions
- ChondroFiller is a non-surgical, cell-free collagen scaffold delivered as an ultrasound-guided outpatient injection. It recruits the patient's own progenitor cells from surrounding tissue rather than harvesting and reintroducing cells. Stem cell therapy collects cells from the patient's bone marrow or fat, processes them, and introduces them into the joint — a more involved, multi-step process with a different biological mechanism. Neither approach cures arthritis, and outcomes vary between individuals.
- Liquid Cartilage is Professor Paul Lee's keyhole surgical protocol. It places the ChondroFiller scaffold arthroscopically and combines it with biological adjuncts — including platelet-rich fibrin, platelet-rich plasma, and, where indicated, the patient's own mesenchymal stem cells (from bone marrow or fat harvested at the same operation). The stem cells act primarily as signalling cells to support the regenerative environment within the scaffold; they are an optional adjunct within the surgical protocol, not a standalone injection.
- Standalone MSC injection is generally considered for patients with early-to-moderate joint wear who are not suitable for or do not wish to undergo surgical intervention. It may provide symptom support and some biological benefit, though the evidence for cartilage regeneration from injected cells alone is less established than for scaffold-based surgical approaches. A specialist assessment is needed to weigh the options for your specific joint and clinical picture.
- The ChondroFiller injection involves no theatre and usually allows a prompt return to normal activity within a few weeks. The Liquid Cartilage surgical procedure requires theatre, an anaesthetic, and a structured rehabilitation programme — typically protected weight-bearing for around two weeks, with graduated return to full activity over several months. Standalone stem cell injection sits between the two in terms of recovery: the aspiration step requires a short procedural visit, but the injection itself does not involve surgery.
- The right choice depends on your specific joint, defect size, degree of wear, activity level, and overall health. A detailed assessment — including appropriate imaging — is needed to evaluate whether the ChondroFiller injection, the Liquid Cartilage surgical protocol with or without MSCs, or another approach is most appropriate. Specialist guidance and realistic expectations are essential before proceeding with any regenerative treatment.
Where to go from here
A few next steps tailored to what you have just read.
Legal & Medical Disclaimer
This article is written by an independent contributor and reflects their own views and experience, not necessarily those of London Cartilage Clinic. It is provided for general information and education only and does not constitute medical advice, diagnosis, or treatment.
Always seek personalised advice from a qualified healthcare professional before making decisions about your health. London Cartilage Clinic accepts no responsibility for errors, omissions, third-party content, or any loss, damage, or injury arising from reliance on this material.
If you believe this article contains inaccurate or infringing content, please contact us at [email protected].
